Fosaprepitant Accord for Chemotherapy-induced nausea and vomiting
Quick answer: Fosaprepitant Accord is used for Chemotherapy-induced nausea and vomiting as part of a nk1 receptor antagonist (antiemetic) treatment regimen. Prodrug of aprepitant — selectively blocks substance P/neurokinin-1 receptors in the CNS to prevent emesis The specific dosing for Chemotherapy-induced nausea and vomiting is determined by your prescriber based on individual factors.
Why is Fosaprepitant Accord used for Chemotherapy-induced nausea and vomiting?
Fosaprepitant Accord belongs to the NK1 receptor antagonist (antiemetic) class. Prodrug of aprepitant — selectively blocks substance P/neurokinin-1 receptors in the CNS to prevent emesis This action makes it useful for treating or managing Chemotherapy-induced nausea and vomiting in patients for whom this approach is clinically appropriate.
It is one of several treatment options. Whether Fosaprepitant Accord is the right choice for a specific patient depends on the type and severity of Chemotherapy-induced nausea and vomiting, response to previous treatments, individual risk factors, and clinical guidelines.
Typical dosing for Chemotherapy-induced nausea and vomiting
Common adult dosing range: 150 mg IV single dose on day 1 of chemotherapy. The actual dose for Chemotherapy-induced nausea and vomiting depends on:
- Severity of the condition
- Patient's age, weight, and organ function
- Other medications being taken
- Treatment response and tolerability
For complete dosing details, see the Fosaprepitant Accord medicine page.
What to expect
Fosaprepitant Accord treatment for Chemotherapy-induced nausea and vomiting typically involves:
- Onset of effect: varies by indication and dose — some effects are immediate, others take days to weeks
- Treatment duration: some courses are short-term, others are long-term or lifelong depending on Chemotherapy-induced nausea and vomiting
- Monitoring: follow-up visits to assess response and adjust dosing
- Side-effect awareness: learning what to expect and what warrants medical attention
Alternatives to consider
If Fosaprepitant Accord is not appropriate or not tolerated, alternatives within the same class or different therapeutic classes may be considered. See all NK1 receptor antagonist (antiemetic) for related options.
When to talk to your doctor
Discuss with your prescriber if you experience:
- Inadequate symptom control on Fosaprepitant Accord
- Side effects affecting daily life
- New medications or supplements that may interact
- Pregnancy planning or pregnancy
- Major changes in health status
Related information
Fosaprepitant Accord full prescribing information · All NK1 receptor antagonist (antiemetic) alternatives
Frequently asked questions
How effective is Fosaprepitant Accord for Chemotherapy-induced nausea and vomiting?
Effectiveness varies by individual response, dose, and severity. Fosaprepitant Accord is one of several treatment options for Chemotherapy-induced nausea and vomiting, supported by clinical evidence within the nk1 receptor antagonist (antiemetic) class. Discuss expected response with your prescriber.
How long do I need to take Fosaprepitant Accord for Chemotherapy-induced nausea and vomiting?
Treatment duration depends on the nature of Chemotherapy-induced nausea and vomiting — some treatments are short-term, others long-term or lifelong. Never stop on your own; discontinuation requires clinical guidance to avoid relapse or rebound effects.
What are the main side effects of Fosaprepitant Accord when used for Chemotherapy-induced nausea and vomiting?
Common and serious side effects are class-related and substance-specific. See the full medicine page for the complete profile. Report any unexpected effects to your prescriber.
Are there alternatives to Fosaprepitant Accord for Chemotherapy-induced nausea and vomiting?
Yes. Multiple medicines and non-drug options exist for Chemotherapy-induced nausea and vomiting. Alternatives within the nk1 receptor antagonist (antiemetic) class share mechanisms; other classes may offer different approaches. Discuss with your clinician.
Last reviewed: by iMedic Medical Editorial Team. Our editorial process.